Brokers Set Expectations for CG Oncology FY2030 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – HC Wainwright issued their FY2030 EPS estimates for CG Oncology in a report issued on Monday, January 26th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of $4.42 for the year. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

Several other equities research analysts also recently issued reports on CGON. The Goldman Sachs Group reiterated a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a research note on Monday, January 12th. Wall Street Zen raised shares of CG Oncology from a “sell” rating to a “hold” rating in a research report on Friday, October 3rd. Wedbush began coverage on CG Oncology in a research report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price objective on the stock. Piper Sandler boosted their price target on CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $67.83.

CG Oncology Price Performance

CG Oncology stock opened at $55.10 on Wednesday. The stock’s 50-day moving average is $44.90 and its 200-day moving average is $37.78. The company has a market cap of $4.44 billion, a price-to-earnings ratio of -27.01 and a beta of 1.35. CG Oncology has a 12 month low of $14.80 and a 12 month high of $57.88.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.57) EPS for the quarter, hitting analysts’ consensus estimates of ($0.57). The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.07 million.

Institutional Investors Weigh In On CG Oncology

A number of institutional investors have recently made changes to their positions in CGON. Mirae Asset Global Investments Co. Ltd. raised its position in shares of CG Oncology by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after acquiring an additional 398 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in CG Oncology by 15.2% in the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock worth $85,000 after purchasing an additional 433 shares during the period. Whittier Trust Co. of Nevada Inc. bought a new stake in CG Oncology during the fourth quarter valued at $27,000. CWM LLC raised its holdings in shares of CG Oncology by 10.9% during the third quarter. CWM LLC now owns 6,865 shares of the company’s stock worth $277,000 after purchasing an additional 672 shares during the period. Finally, Strengthening Families & Communities LLC acquired a new stake in shares of CG Oncology during the third quarter worth $40,000. 26.56% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director James Mulay sold 11,145 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $52.47, for a total value of $584,778.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $41.43, for a total value of $41,430.00. The SEC filing for this sale provides additional information.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.